{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:18:55Z","timestamp":1787624335397,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["24ck0106943h0001"],"award-info":[{"award-number":["24ck0106943h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25ck0106943s0302"],"award-info":[{"award-number":["25ck0106943s0302"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["26ck0106943s0303"],"award-info":[{"award-number":["26ck0106943s0303"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K11632"],"award-info":[{"award-number":["25K11632"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["023K15330"],"award-info":[{"award-number":["023K15330"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>To identify strategies to prevent the induction of monocytic myeloid\u2010derived suppressor cells (M\u2010MDSCs) in multiple myeloma (MM), we analysed molecular changes in myeloma and myeloid cells within peripheral blood mononuclear cells (PBMCs) that promote M\u2010MDSC induction during co\u2010culture. We then examined the effects of cereblon E3 ligase modulators (CELMoDs), iberdomide (IBER) and mezigdomide (MEZI), compared with pomalidomide (POM), on M\u2010MDSC induction from PBMCs during co\u2010culture with human myeloma\u2010derived cell lines (HMCLs). Co\u2010culturing PBMCs with HMCLs increased inflammatory, interleukin (IL)\u20106\u2010Janus kinase\u2010signal transducer and activator of transcription (JAK\u2010STAT)3 and tumour necrosis factor (TNF)\u2010\u03b1\u2010associated gene expression in HMCLs, while decreasing interferon\u2010related genes in myeloid cells. CELMoDs inhibited M\u2010MDSC induction, with 7.5\u2009nM IBER and 1\u2009nM MEZI as effective as 1\u2009\u03bcM POM. In this context, CELMoDs and POM reduced inflammatory genes, including those involved in TNF\u2010\u03b1 signalling via nuclear factor\u2010kappa B (NF\u2010\u03baB), in HMCLs and lowered pro\u2010inflammatory genes, including C\u2010C motif chemokine ligand 5 (CCL5). Conversely, in myeloid cells, CELMoDs and POM enhanced immune\u2010activating pathways linked to interferon responses. Furthermore, CELMoDs and POM reduced candidate soluble mediators associated with M\u2010MDSC induction, such as migration\u2010inhibitory factor (MIF) and IL\u201010, in myeloid cells and decreased IL\u201010 secretion from IL\u201010\u2010producing HMCLs. In summary, CELMoDs effectively inhibit M\u2010MDSC induction by altering gene expression in co\u2010cultured HMCLs and myeloid cells, while also suppressing mediators like IL\u201010 and MIF.<\/jats:p>","DOI":"10.1111\/bjh.70787","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:20:03Z","timestamp":1787620803000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cellular and molecular impacts of\n                    <scp>CELMoDs<\/scp>\n                    and\n                    <scp>IMiD<\/scp>\n                    on the induction of myeloid\u2010derived suppressor cells by myeloma cells"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5503-5698","authenticated-orcid":false,"given":"Yui","family":"Niiyama\u2010Uchibori","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-5491","authenticated-orcid":false,"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3775-5496","authenticated-orcid":false,"given":"Shotaro","family":"Chinen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9954-8462","authenticated-orcid":false,"given":"Takahisa","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3003-9015","authenticated-orcid":false,"given":"Hiroaki","family":"Nagata","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-3728","authenticated-orcid":false,"given":"Haruya","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7817-093X","authenticated-orcid":false,"given":"Takahiro","family":"Fujino","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-1755","authenticated-orcid":false,"given":"Shinsuke","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-7902","authenticated-orcid":false,"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"},{"name":"Department of Blood Transfusion Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-1550","authenticated-orcid":false,"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine Kyoto Prefectural University of Medicine Graduate School of Medical Science  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"22","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon T","year":"2019","journal-title":"N Engl J Med"},{"issue":"10214","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low\u2010dose dexamethasone versus pomalidomide and low\u2010dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA\u2010MM): a randomised, multicentre, open\u2010label, phase 3 study","volume":"394","author":"Attal M","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus Pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT\u20103 trial","volume":"41","author":"Dimopoulos MA","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10218","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open\u2010label, phase 3 trial","volume":"395","author":"Mateos MV","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study","volume":"13","author":"Martin T","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"e003975","DOI":"10.1136\/jitc-2021-003975","article-title":"Tumor\u2010associated macrophages in multiple myeloma: advances in biology and therapy","volume":"10","author":"Sun J","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"9","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092018","article-title":"Overcoming the immunosuppressive tumor microenvironment in multiple myeloma","volume":"13","author":"Uckun FM","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41375-024-02391-8","article-title":"IL\u201010R inhibition reprograms tumor\u2010associated macrophages and reverses drug resistance in multiple myeloma","volume":"38","author":"Sun J","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid\u2010derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu J","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid\u2010derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte V","year":"2016","journal-title":"Nat Commun"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.740827","article-title":"Myeloid\u2010derived suppressor cells: A multifaceted accomplice in tumor progression","volume":"9","author":"Cheng JN","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.16881","article-title":"Lenalidomide and pomalidomide potently interfere with induction of myeloid\u2010derived suppressor cells in multiple myeloma","volume":"191","author":"Kuwahara\u2010Ota S","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bjh.19049","article-title":"Tumour\u2010derived exosomes promote the induction of monocytic myeloid\u2010derived suppressor cells from peripheral blood mononuclear cells by delivering miR\u2010106a\u20105p and miR\u2010146a\u20105p in multiple myeloma","volume":"203","author":"Mizuhara K","year":"2023","journal-title":"Br J Haematol"},{"issue":"11","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson PG","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late\u2010line relapsed or refractory multiple myeloma (CC\u2010220\u2010MM\u2010001): a multicentre, multicohort, open\u2010label, phase 1\/2 trial","volume":"9","author":"Lonial S","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6619","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson ER","year":"2022","journal-title":"Science"},{"issue":"13","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC\u201092480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen JD","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40364-025-00825-8","article-title":"Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma","volume":"13","author":"Kegyes D","year":"2025","journal-title":"Biomark Res"},{"issue":"22","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.2024025861","article-title":"Evaluating the impact of CRBN mutations on response to immunomodulatory drugs and novel cereblon E3 ligase modulators in myeloma","volume":"145","author":"Chrisochoidou Y","year":"2025","journal-title":"Blood"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2026.153287"},{"issue":"3","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy\u2010to\u2010use software EZR for medical statistics","volume":"48","author":"Kanda Y","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/17534259231172079","article-title":"Increased circulating monocyte MDSCs positively correlate with serum Interleukin\u201010 in metastatic melanoma patients","volume":"29","author":"Mirjacic Martinovic K","year":"2023","journal-title":"Innate Immun"},{"issue":"4","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/bjc.2016.11","article-title":"High level of interleukin\u201010 in serum predicts poor prognosis in multiple myeloma","volume":"114","author":"Wang H","year":"2016","journal-title":"Br J Cancer"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cellimm.2018.07.003","article-title":"IL\u201010 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development","volume":"332","author":"Bah I","year":"2018","journal-title":"Cell Immunol"},{"issue":"1","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1186\/s12885-024-13124-6","article-title":"Clinical and immunological characteristics of high\u2010risk double\u2010hit multiple myeloma","volume":"24","author":"Shang Y","year":"2024","journal-title":"BMC Cancer"},{"issue":"13","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.2021014701","article-title":"Overcoming IMiD resistance in T\u2010cell lymphomas through potent degradation of ZFP91 and IKZF1","volume":"139","author":"Wu W","year":"2022","journal-title":"Blood"},{"issue":"11","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1631\/jzus.B2200277","article-title":"High levels of serum IL\u201010 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma","volume":"23","author":"Yue X","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"issue":"2","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgaf033","article-title":"Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: clinical significance and in\u00a0vitro effects","volume":"46","author":"Li D","year":"2025","journal-title":"Carcinogenesis"},{"issue":"4","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich DI","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.4049\/jimmunol.1201161","article-title":"Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid\u2010derived suppressor cells in the tumor microenvironment","volume":"189","author":"Simpson KD","year":"2012","journal-title":"J Immunol"},{"issue":"8","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/stem.2393","article-title":"Cancer stem cell\u2010secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion","volume":"34","author":"Otvos B","year":"2016","journal-title":"Stem Cells"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.609948","article-title":"MIF\u2010dependent control of tumor immunity","volume":"11","author":"Noe JT","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1201650","article-title":"Control of tumor\u2010associated macrophage alternative activation by macrophage migration inhibitory factor","volume":"190","author":"Yaddanapudi K","year":"2013","journal-title":"J Immunol"},{"issue":"2","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/2326-6066.CIR-15-0070-T","article-title":"MIF is necessary for late\u2010stage melanoma patient MDSC immune suppression and differentiation","volume":"4","author":"Yaddanapudi K","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"6168","key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke J","year":"2014","journal-title":"Science"},{"issue":"6168","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon\u2010dependent destruction of Ikaros proteins","volume":"343","author":"Lu G","year":"2014","journal-title":"Science"},{"issue":"6","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101571","article-title":"Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma","volume":"5","author":"Amatangelo M","year":"2024","journal-title":"Cell Rep Med"},{"issue":"32","key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"53053","DOI":"10.18632\/oncotarget.18085","article-title":"Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties","volume":"8","author":"Costa F","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter\u2010regulatory immunosuppressive changes in myeloma patients","volume":"177","author":"Busch A","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41467-021-22033-2","article-title":"Immune suppressive activity of myeloid\u2010derived suppressor cells in cancer requires inactivation of the type I interferon pathway","volume":"12","author":"Alicea\u2010Torres K","year":"2021","journal-title":"Nat Commun"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70787","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:20:13Z","timestamp":1787620813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":41,"alternative-id":["10.1111\/bjh.70787"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70787","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2026-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bjh.70787"}}